New Hope for Serious Fungal Infections
Taylor Sandison, MD, MPH
Cidara Therapeutics, Inc., San Diego, CA, USA

About Us
At A Glance
- Cidara Therapeutics, Inc. (Nasdaq: CDTX) is a clinical-stage biotechnology company focused on novel anti-infectives and immunotherapies
- Headquartered in San Diego, CA
- Since 2014: 49 employees

Our Mission
To improve patients’ lives through the discovery, development and commercialization of novel, best-in-class anti-infectives.

Unmet Needs
Fungal infections: high mortality
- U.S. 12 Week Mortality per Annun by Species
  - Candida: 67,500
  - Aspergillus: 22,500
  - Cryptococcus: 4,500
  - Rare Fungi: 2,500

Vulvovaginal candidiasis (VVC): widespread condition with high unmet need
- RVVC: 4.5 million annually (no drugs approved)
- Cervical: 75% of all women

Pipeline

Program

CD101 IV
- Candidemia/Invasive Candidiasis

CD101 Topical
- Acute and Recurrent VVC

Cloudbreak™ Platform
- Small and Large Molecule Programs
  - Antifungal
  - Antibacterial
  - Antiviral

Program

Indication

Discovery

Research

In Vivo

In Vivo ND

Ph 1

Ph 2

CD101 IV
- Candidemia/Invasive Candidiasis

CD101 Topical
- Acute and Recurrent VVC

Cloudbreak™ Platform
- Small and Large Molecule Programs
  - Antifungal
  - Antibacterial
  - Antiviral

Summary

CD101 IV
- Invasive fungal infections
- Highly differentiated echinocandin
- High, front-loaded drug exposures
- Once weekly dosing
- Inpatient and Outpatient
- Positive Phase 1 data
- Begin Phase 2 in candidemia 2Q 2016

CD101 Topical
- Acute VVC / RVVC
- First topical echinocandin
- Highly potent, minimal systemic exposure

Cloudbreak™
- Infectious disease immunotherapy
- Candidate selection in 2016